Medina Aixa, Carballo Jeismar, González-Marcano Eglys, Blanca Isaac, Convit Ana F
Jacinto Convit World Organization Inc. Pompano Beach Florida USA.
Facultad de Medicina Universidad Central de Venezuela Caracas Venezuela.
Cancer Innov. 2024 Sep 22;3(5):e140. doi: 10.1002/cai2.140. eCollection 2024 Oct.
Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide. With increased knowledge regarding tumor escape mechanisms and advances in immunology, many new antitumor strategies such as nonspecific immunotherapies, monoclonal antibodies, anticancer vaccines, and oncolytic viruses, among others, make immunotherapy a promising approach for the treatment of BC. However, these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers. In this article, we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.
乳腺癌(BC)是全球女性中最常见的恶性肿瘤及主要死因。随着对肿瘤逃逸机制的认识增加和免疫学的进展,许多新的抗肿瘤策略,如非特异性免疫疗法、单克隆抗体、抗癌疫苗和溶瘤病毒等,使免疫疗法成为治疗BC的一种有前景的方法。然而,由于耐药性和适度的反应率仍然是重要障碍,这些方法仍需要仔细评估和调整。在本文中,我们旨在总结BC免疫疗法的最新可用数据,包括正在进行的临床试验结果以及作为单一疗法或与传统治疗联合使用的已批准疗法。